Fekadu Ginenus, Yao Jiaqi, You Joyce H S
School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, N.T, Hong Kong.
Expert Rev Pharmacoecon Outcomes Res. 2021 Oct;21(5):897-910. doi: 10.1080/14737167.2021.1925111. Epub 2021 Jun 23.
: There is a rising global interest in the pharmacoeconomic evaluations of bedaquiline (BDQ), a novel oral diarylquinoline, for treatment of drug-resistant tuberculosis (DR-TB).: This article systematically reviewed publications retrieved from Medline, American Psychological Association-Psychology information, Web of Science, Embase, Scopus, Science direct, Center for Reviews and Dissemination, and CINAHL Complete during 2010-2020 on pharmacoeconomic studies on BDQ for DR-TB treatment. Ten Markov model-based cost-effectiveness analyses identified were conducted in high (n = 4), intermediate (n = 2), and low (n = 4) TB burden countries.: The paucity of model-based health economic analyses on BDQ-containing regimens for DR-TB indicated that further pharmacoeconomic research of BDQ-based regimens, on the aspects of duration of BDQ treatment, types of DR-TB indicated, and settings of regions and health-systems, is highly warranted to inform global cost-effective use of BDQ-based regimens for DR-TB treatment.
全球对新型口服二芳基喹啉类药物贝达喹啉（BDQ）用于治疗耐多药结核病（DR-TB）的药物经济学评价的兴趣日益浓厚。本文系统回顾了2010年至2020年期间从Medline、美国心理学会心理学数据库、科学引文索引、Embase、Scopus、Science direct、循证医学图书馆和护理学与健康领域数据库中检索到的关于BDQ治疗DR-TB的药物经济学研究出版物。在高结核病负担国家（n = 4）、中等结核病负担国家（n = 2）和低结核病负担国家（n = 4）进行了十项基于马尔可夫模型的成本效益分析。基于模型的含BDQ方案治疗DR-TB的卫生经济分析较少，这表明在BDQ治疗持续时间、DR-TB类型以及地区和卫生系统环境等方面，对基于BDQ的方案进行进一步的药物经济学研究非常有必要，以便为全球有效使用基于BDQ的方案治疗DR-TB提供依据。
